Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 25070908 | HLA (HLA) | primary graft dysfunction | NA | NA | NA | unclassified | |
| retransplantation (odds ratio [or] = 2.7, 95% confidence interval [ci] 1.1 to 6.5, p = 0.03), pre-operative hla antibodies (or = 2.1, 95% ci 1.2 to 3.4, p = 0.003) and primary graft dysfunction (pgd) score grade 2 or 3 at 48 hours (or = 2.6, 95% ci 1.5 to 4.6, p = 0.001) were associated with early dsa development. | |||||||
| 25447575 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | lung transplantation | NA | NA | NA | unclassified | |
| de novo donor-specific anti-human leukocyte antigen antibodies develop in a high proportion of lung transplant recipients early after lung transplantation. | |||||||
| 26429328 | HLA (HLA) | lung transplantation | NA | NA | NA | only_studied | |
| using solid phase assays to define sensitization, we assessed the relationship between pra status, donor specific anti-hla antibodies (dsa) pre-transplant, cytotoxic cross match results and the clinical outcomes following lung transplantation. | |||||||
| 26429328 | MHC (MHC) | lung transplantation | NA | NA | NA | unclassified | |
| luminex assays determined the presence of antibodies to class i and class ii mhc molecules prior to lung transplantation. | |||||||
| 26714123 | HLA (HLA) | lung transplantation | NA | NA | NA | unclassified | |
| igm-enriched human intravenous immunoglobulin-based treatment of patients with early donor specific anti-hla antibodies after lung transplantation. | |||||||
| 26714123 | HLA (HLA) | lung transplantation | NA | NA | NA | unclassified | |
| at our institution, until april 2013, patients who showed early donor specific anti-hla antibodies (dsa) after lung transplantation were preemptively treated with therapeutic plasma exchange (tpe) and a single dose of rituximab. | |||||||
| 26967790 | NA (NA) | lung transplantation | NA | NA | NA | unclassified | |
| de novo dq donor-specific antibodies are associated with chronic lung allograft dysfunction after lung transplantation. | |||||||
| 26967790 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | lung transplantation | NA | NA | NA | positive | |
| rationaledespite increasing evidence about the role of donor-specific human leukocyte antigen (hla) antibodies in transplant outcomes, the incidence and impact of de novo donor-specific antibodies (dndsa) after lung transplantation remains unclear. | |||||||
| 26967790 | NA (NA) | lung transplantation | NA | NA | NA | unclassified | |
| dndsa are common after lung transplantation, with the majority being dq dsa. | |||||||
| 27278097 | HLA (HLA) | lung transplantation | NA | NA | NA | unclassified | |
| we concluded that exosomes expressing donor hla, sags and immunoregulatory mirnas are present in the circulation and local site after human lung transplantation and play an important role in the immune pathogenesis of acute allograft rejection and bos. | |||||||
Copyright 2024